Intas Pharmaceuticals Limited — Fluoxetine Exporter Profile
Indian Pharmaceutical Exporter · #2 for Fluoxetine · $4.8M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #2 Indian exporter of Fluoxetine with $4.8M in export value and 97 verified shipments. Intas Pharmaceuticals Limited holds a 2.1% market share in Fluoxetine exports across 7 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Fluoxetine Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Fluoxetine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $1.9M | 72 | 89.9% |
| NETHERLANDS | $191.4K | 13 | 9.0% |
| MAURITIUS | $15.2K | 2 | 0.7% |
| ZAMBIA | $4.5K | 1 | 0.2% |
| ITALY | $1.3K | 17 | 0.1% |
| JAMAICA | $1.3K | 2 | 0.1% |
| BARBADOS | $619 | 1 | 0.0% |
Intas Pharmaceuticals Limited exports Fluoxetine to 7 countries. The largest destination is CANADA accounting for 89.9% of Intas Pharmaceuticals Limited's Fluoxetine shipments, followed by NETHERLANDS (9.0%) and MAURITIUS (0.7%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fluoxetine from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD HEALTHCARE INC. | CANADA | $403.7K | 15 |
| ACCORD HEALTHCARE INC., | CANADA | $403.5K | 12 |
| ACCORD HEALTHCARE INC | CANADA | $322.0K | 15 |
| JAMP PHARMA CORPORATION | CANADA | $319.3K | 13 |
| ACCORD HEALTHCARE INC, | CANADA | $200.0K | 4 |
| BROCACEF NL : HUB | NETHERLANDS | $88.0K | 3 |
| MANTRA DISTRIBUTIONS INC | CANADA | $75.2K | 4 |
| BROCACEF NL:HUB | NETHERLANDS | $66.3K | 2 |
| BIOMEDPHARMA | CANADA | $66.3K | 2 |
| BIOMED PHARMA | CANADA | $41.7K | 1 |
Intas Pharmaceuticals Limited supplies Fluoxetine to 23 buyers globally. The largest buyer is ACCORD HEALTHCARE INC. (CANADA), followed by ACCORD HEALTHCARE INC., (CANADA) and ACCORD HEALTHCARE INC (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fluoxetine Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $59.0M worth of Fluoxetine through 3,702 shipments from 253 suppliers to 101 countries, serving 522 buyers globally. Intas Pharmaceuticals Limited contributes $4.8M to this total, accounting for 2.1% of India's Fluoxetine exports. Intas Pharmaceuticals Limited ships Fluoxetine to 7 countries through 23 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Fluoxetine Exports?
Intas Pharmaceuticals Limited's average Fluoxetine shipment value is $50.0K per consignment, based on 97 shipments totaling $4.8M. The largest destination is CANADA (89.9% of Intas Pharmaceuticals Limited's Fluoxetine exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Fluoxetine Exporters?
Intas Pharmaceuticals Limited ranks #2 among 253 Indian Fluoxetine exporters with a 2.1% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($10.9M), MICRO LABS LIMITED ($7.7M), ALEMBIC PHARMACEUTICALS LIMITED ($5.8M). Intas Pharmaceuticals Limited processed 97 shipments to 7 destination countries.
What Fluoxetine Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL DRUGS AND MEDICINE PRACH-FLUOXETINE 20 EACH HARD GELATIN CAPSULECONTAINS FLUOXETINE HYDROCHLORIDE PH. | $200.0K | 4 |
| PHARMA DRUGS AND MEDI JAMP-FLUOXETINE CAPSULES 20MG AS PER INV | $170.5K | 4 |
| PH.DRU.& MED.: ACH FLUOXETINE 20MG CAPSU | $130.5K | 3 |
| PHARMA DRUGS & MEDI: FLUOXETINE CAPSULES | $119.5K | 4 |
| PH.DRU.& MED.: FLUOXETINE CAPSULES BP 20 | $102.5K | 3 |
| PHARMA DRUGS & MEDI Fluoxetine Accord 20 | $88.0K | 3 |
| PH.DRU.& MED.: FLUOXETINE CAPSULES BP 10 | $87.0K | 4 |
| PHARMA DRUGS & MEDI: ACH FLUOXETINE 20MG | $80.8K | 2 |
| PHARMA DURGS AND MEDI JAMP-FLUOXETINE CA | $73.1K | 4 |
| PHARMA DRUG&MED:Fluoxetine Accord 20mg E | $66.3K | 2 |
Intas Pharmaceuticals Limited exports 54 distinct Fluoxetine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL DRUGS AND MEDICINE PRACH-FLUOXETINE 20 EACH H with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Fluoxetine to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Fluoxetine to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Fluoxetine Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | MARKSANS PHARMA LIMITED | $5.6M | 168 | 3 | $33.3K |
| 1 | SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED | $5.0M | 99 | 1 | $50.0K |
| 2 | INTAS PHARMACEUTICALS LIMITED ★ | $4.8M | 97 | 7 | $50.0K |
| 8 | DR.REDDY'S LABORATORIES LTD | $4.7M | 172 | 7 | $27.3K |
| 9 | APL HEALTHCARE LIMITED | $3.6M | 73 | 1 | $48.9K |
Intas Pharmaceuticals Limited ranks #2 among 253 Indian Fluoxetine exporters. Average shipment value of $50.0K compared to the market average of $233.1K. The closest competitors by value are MARKSANS PHARMA LIMITED and SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED.
Which Indian Ports Ship Fluoxetine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 603 | 16.3% |
| SAHAR AIR | 508 | 13.7% |
| NHAVA SHEVA SEA (INNSA1) | 285 | 7.7% |
| MUNDRA SEA | 150 | 4.1% |
| MUNDRA SEA (INMUN1) | 129 | 3.5% |
| Bombay Air | 119 | 3.2% |
| DELHI AIR | 110 | 3.0% |
| HYDERABAD ICD (INSNF6) | 108 | 2.9% |
What Other CNS & Psychiatric Products Does Intas Pharmaceuticals Limited Export?
Intas Pharmaceuticals Limited also exports these cns & psychiatric products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Fluoxetine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Fluoxetine, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fluoxetine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fluoxetine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 108 individual customs records matching Intas Pharmaceuticals Limited exporting Fluoxetine, covering 54 formulations to 7 countries via 23 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 101+ countries, 522+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fluoxetine Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Fluoxetine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Fluoxetine Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fluoxetine. For current shipment-level data, contact TransData Nexus.